Who will develop new antibacterial agents?

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1645, 2014, Pages

  Cole, Stewart T ^a  

^a EPFL   (Switzerland)

Author keywords

Antibiotics; Biotechnology; Drug discovery; Drug resistance; Pharmaceutical industry

Indexed keywords

BIOTECHNOLOGY; DRUG DEVELOPMENT; DRUG RESISTANCE; MEDICINE; MEMORY; PHARMACEUTICAL INDUSTRY; PUBLIC SECTOR;

EID: 84900306147     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0430     Document Type: Review

References (26)

1. Hopwood DA. 2007 Streptomyces in nature and medicine: the antibiotic makers. Oxford, UK: Oxford University Press.
2. Walsh C. 2003 Antibiotics: actions, origins, resistance. Washington, DC: ASM Press.
3. Henderson DA. 1987 Principles and lessons from the smallpox eradication programme. Bull. World Health Organ. 65, 535-546.
4. WHO 2012 See http://www.who.int/mediacentre/ factsheets/fs310/en/index2.html.
5. ECDC/EMEA 2009 The bacterial challenge: time to react. London, UK: European Centre for Disease Control & European Medicines Agency.
6. CDC 2013 Antibiotic resistance threats in the United States, 2013 1-114. See http://www.cdc.gov/ drugresistance/threat-report-2013/.
7. IDSA 2013 See http://www.idsociety.org/AR_Facts/.
8. Kumarasamy KK et al. 2010 Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10, 597-602. (doi:10.1016/S1473-3099(10)70143-2)
9. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009 Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12. (doi:10.1086/595011)
10. Karesh WB et al. 2012 Ecology of zoonoses: natural and unnatural histories. Lancet 380, 1936-1945. (doi:10.1016/S0140-6736(12)61678-X)
11. Witte W. 1998 Medical consequences of antibiotic use in agriculture. Science 279, 996-997. (doi:10. 1126/science.279.5353.996)
12. European Commission 2005 Ban on antibiotics as growth promoters in animal feed enters into effect 2005. IP/05/1687 22/12/2005. See http://europa.eu/ rapid/press-release_IP-05-1687_en.htm.
13. Fischbach MA, Walsh CT. 2009 Antibiotics for emerging pathogens. Science 325, 1089-1093. (doi:10.1126/science.1176667)
14. von Nussbaum F, Brands M, Hinzen B, Weigand S, Habich D. 2006 Antibacterial natural products in medicinal chemistry: exodus or revival? Angew. Chem. 45, 5072-5129. (doi:10.1002/anie.200600350)
15. Demain AL. 2011 Antibiotic discovery: a step in the right direction. Chem. Biol. 18, 939. (doi:10.1016/j. chembiol.2011.08.002)
16. Barrett JF. 2005 Can biotech deliver new antibiotics? Curr. Opin. Microbiol. 8, 498-503. (doi:10.1016/j. mib.2005.08.007)
17. Palmisano L, Vella S. 2011 A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann. Istituto Superiore Sanita 47, 44-48.
18. Zumla A, Nahid P, Cole ST. 2013 Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388-404. (doi:10.1038/nrd4001)
19. Diacon AH et al. 2009 The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397-2405. (doi:10.1056/ NEJMoa0808427)
20. Gler MT et al. 2012 Delamanid for multidrugresistant pulmonary tuberculosis. N. Engl. J. Med. 366, 2151-2160. (doi:10.1056/NEJMoa1112433)
21. Diacon AH et al. 2012 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380, 986-993. (doi:10.1016/S0140-6736(12)61080-0)
22. Lipinski C. 2000 Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249. (doi:10.1016/S1056-8719(00)00107-6)
23. Médecins Sans Frontieres/Doctors without Borders. 2014 Accelerating innovation and access to medicines for tuberculosis through open collaboration: a push, pull, pool approach ("the 3P Project").
24. BCG 2011 Life sciences R&D: changing the innovation equation in India 2011. See http:// www.bcg.com/expertise_impact/biopharma_ summit.aspx.
25. Lachmann PJ. 2012 The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals. Q. J. Med. 105, 1179-1189. (doi:10.1093/qjmed/hcs148)
26. Pringle P. 2012 Experiment eleven. Deceit and betrayal in the discovery of the cure for tuberculosis. London, UK: Bloomsbury.